Anti-IgE and other antibody targets in asthma

Handbook of Experimental Pharmacology

Volumn 181, Issue , 2008, Pages 257-288

  Singh, J ^a   Kraft, M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; IMMUNOGLOBULIN E; INTERLEUKIN DERIVATIVE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ASTHMA; HUMAN; IMMUNOLOGY; PATHOPHYSIOLOGY; REVIEW; TREATMENT OUTCOME;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; HUMANS; IMMUNOGLOBULIN E; INTERLEUKINS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38449109458     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-540-73259-4_12     Document Type: Article

References (131)

1. Adis (2002) Omalizumab. Biodrugs 16:380-386
2. Amiri P, Haak-Frendscho M, Robbins K, McKerrow JH, Stewart T, Jardieu P (1994) Antiimmunoglobulin E treatment decreases worm burden and egg production in Schistosoma mansoni-infected normal and interferon gamma knockout mice. J Exp Med 180:43-51
3. Avila PC (2007) Does Anti-IgE Therapy Help in Asthma? Efficacy and Controversies. Annu Rev Med 58
4. Barnes PJ (2003) Cytokine-directed therapies for the treatment of chronic airway diseases. Cytokine Growth Factor Rev 14:511-522
5. Bayram H, Sapsford RJ, Abdelaziz MM, Khair OA (2001) Effect of ozone and nitrogen dioxide on the release of proinflammatory mediators from bronchial epithelial cells of nonatopic nonasthmatic subjects and atopic asthmatic patients in vitro. J Allergy Clin Immunol 107:287-294
6. Beck LA, Marcotte GV, MacGlashan JD, Togias A, Saini S (2004) Omalizumab-induced reductions in mast cell Fc RI expression and function. J Allergy Clin Immunol 114:527-530
7. Bennett AN, Wong M, Zain A, Panayi G, Kirkham B (2005) Adalimumab-induced asthma. Rheumatology 44:1199-1200
8. Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, Bradding P, Brightling CE, Wardlaw AJ, Pavord ID (2006) Evidence of a role of tumor necrosis factor {alpha} in refractory asthma. N Engl J Med 354:697-708
9. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275-2285
10. Borish L, Chipps B, Deniz Y, Gujrathi S, Zheng B, Dolan C (2005) Total serum IgE levels in a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 95:247-253
11. Borish LC, Nelson HS, Corren J, Bensch G, Busse WW (2001) Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 107:963-970
12. Bosson J, Stenfors N, Bucht A, Helleday R, Pourazar J, Holgate ST, Kelly FJ, Sandstrom T, Wilson S, Frew AJ, Blomberg A (2003) Ozone-induced bronchial epithelial cytokine expression differs between healthy and asthmatic subjects. Clin Exp Allergy 33:777-782
13. Boulet L-P, Chapman KR, Cote J, Kalra S, Bhagat R, Swystun VA, Laviolette M, Cleland LD, Deschesnes F, Su JQ, Devault A, Fick RB, Cockcroft DW(1997) Inhibitory effects of an Anti- IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 155:1835-1840
14. Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, Fox H, Hedgecock S, Blogg M, Cioppa GD (2005) The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 60:302-308
15. Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H (2004) Predicting Response to Omalizumab, an Anti-IgE Antibody, in Patients With Allergic Asthma. Chest 125:1378-1386
16. Bradding P, Walls AF, Holgate ST (2006) The role of the mast cell in the pathophysiology of asthma. J Allergy Clin Immunol 117:1277-1284
17. Braman SS (2006) The Global Burden of Asthma. Chest 130:4S-12
18. Bresnihan B, Cunnane G (2003) Infection complications associated with the use of biologic agents. Rheum Dis Clin North Am 29:185-202
19. Broide DH (2001) Molecular and cellular mechanisms of allergic disease. J Allergy Clin Immunol 108:S65-S71
20. Buhl R (2003) Omalizumab (Xolair) improves quality of life in adult patients with allergic asthma: a review. Respir Med 97:123-129
21. Buhl R (2004) Anti-IgE antibodies for the treatment of asthma. Curr Opin Pulm Med 11:27-34
22. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N (2001) Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108:184-190
23. Casale TB, Bernstein IL, Busse WW, LaForce CF, Tinkelman DG, Stoltz RR, Dockhorn RJ, Reimann J, Su JQ (1997) Use of an anti-IgE humanized monoclonal antibody in ragweedinduced allergic rhinitis. J Allergy Clin Immunol 100:110-121
24. Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG, Mokhtarani M, Seyfert- Margolis V, Asare A, Bateman K (2006) Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 117:134-140
25. Chang TW (2000) The pharmacological basis of anti-IgE therapy. Nat Biotech 18:157-162
26. Chinn S (2006) Obesity and asthma. Paediatr Respir Rev 7:223-228
27. Cohen RT, Celedon JC, Hinckson VJ, Ramsey CD, Wakefield DB, Weiss ST, Cloutier MM (2006) Health-Care Use Among Puerto Rican and African-American Children With Asthma. Chest 130:463-471
28. Covar RA, Spahn JD, Martin RJ, Silkoff PE, Sundstrom DA, Murphy J, Szefler SJ (2004) Safety and application of induced sputum analysis in childhood asthma. J Allergy Clin Immunol 114:575-582
29. Dillman R (1989) Monoclonal antibodies for treating cancer. Ann Intern Med 111:592-603
30. Dixon AE, Kaminsky DA, Holbrook JT, Wise RA, Shade DM, Irvin CG (2006) Allergic rhinitis and sinusitis in asthma: Differential effects on symptoms and pulmonary function. Chest 130:429-435
31. Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, Bao W, Fowler-Taylor A, Matthews J, Busse WW, Holgate ST, Fahy JV (2004) Effects of treatment with antiimmunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 170:583-593
32. Dolan C, Fraher K, Bleecker E, Borish LC, B, Hayden M,Weiss S, Zheng B, Johnson C,Wenzel S (2004) Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 92:32-39
33. Dolovich J, Hargreave FE, Chalmers R, Shier KJ, Gauldie J, Bienenstock J (1973) Late cutaneous allergic responses in isolated IgE-dependent reactions. J Allergy Clin Immunol 52:38-46
34. Eder W, Ege MJ, von Mutius E (2006) The asthma epidemic. N Engl J Med 355:2226-2235
35. Erin EM, Leaker BR, Nicholson GC, Tan AJ, Green LM, Neighbour H, Zacharasiewicz AS, Turner J, Barnathan ES, Kon OM, Barnes PJ, Hansel TT (2006) The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit. Care Med 174:753-762
36. Erzurum SC (2006) Inhibition of tumor necrosis factor α for refractory asthma. N Engl J Med 354:754-758
37. Fahy J, Cockcroft D, Boulet L,Wong H, Deschesnes F, Dvid E, Ruppel J, Su J, Adelman D (1999) Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Am J Respir Crit Care Med 160
38. Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, Fick RB, Boushey HA (1997) The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 155:1828-1834
39. Flood-Page P, Menzies-Gow A, Phipps S, Ying S,Wangoo A, Ludwig MS, Barnes N, Robinson D, Kay AB (2003a) Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 112:1029-1036
40. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS (2003b) Eosinophils role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 167:199-204
41. Geiger E, Magerstaedt R, Weendorf JHM, Kraft S, Hanau D, Bieber T (2000) IL-4 induces the intracellular expression of the α chain of the high-affinity receptor for IgE in in vitro-generated dendritic cells. J Allergy Clin Immunol 105:150-156
42. Genentech-Inc (2003) Briefing document on safety of omalizumab (Xolair) for treatment of allergic asthma (BLA STN 103976/0). Food and Drug Administration, Washington, DC Genentech (2003) Omalizumab prescribing information. South San Francisco, CA
43. Giles JT, Bathon JM (2004) Serious Infections Associated with Anticytokine Therapies in the Rheumatic Diseases. J Intensive Care Med 19:320-334
44. Gold DR, Wright R (2005) Population disparities in asthma. Ann Rev Public Health 26:89-113
45. Gosset P, Tsicopoulos A, Wallaert B, Vannimenus C, Joseph M, Tonnel A-B, Capron A (1991) Increased secretion of tumor necrosis factor α and interleukin-6 by alveolar macrophages consecutive to the development of the late asthmatic reaction. J Allergy Clin Immunol 88:561-571
46. Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, Sheppard D, Mohrs M, Donaldson DD, Locksley RM, Corry DB (1998) Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282:2261-2263
47. Gulliver T, Eid N (2005) Effects of glucocorticoids on the hypothalamic-pituitary-adrenal axis in children and adults. Immunol Allergy Clin North Am 25:541-555
48. Hajiro T, Nishimura K (2002) Minimal clinically significant difference in health status: the thorny path of health status measures? Eur Respir J 19:390-391
49. Hakonarson H, Carter C, Kim C, Grunstein M (1999) Altered expression and action of the low-affinity IgE receptor FcRII (CD23) in asthmatic airway smooth muscle. J Allergy Clin Immunol 104:575-584
50. Harding (2005) Gastroesophageal reflux: a potential asthma trigger. Immunol Allergy Clin N Am 25:131-148
51. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE (2005) The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 34:819-836
52. Hochhaus G, Brookman L, Fox H, Johnson C, Matthews J, Ren S, Deniz Y (2003) Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 19:491-498
53. Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB, Chung KF, Bousquet J, Kerstjens HA, Fox H, Thirlwell J, Cioppa GD (2004) Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 34:632-638
54. Holt P, Macaubas C, Stumbles P, Sly P (1999) The role of allergy in the development of asthma. Nature 402:B12-B17
55. Howarth PH, Babu KS, Arshad HS, Lau L, Buckley M, McConnell W, Beckett P, Al Ali M, Chauhan A, Wilson SJ, Reynolds A, Davies DE, Holgate ST (2005) Tumour necrosis factor (TNFα) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 60:1012-1018
56. Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, BloggM, Surrey K (2005) Benefits of omalizumab as addon therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60:309-316
57. Humbert M, Durham SR, Kimmitt P, Powell N, Assoufi B, Pfister R,Menz G, Kay AB, Corrigan CJ (1997) Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. J Allergy Clin Immunol 99:657-665
58. Hyams JS, Markowitz J, Wyllie R (2000) Use of infliximab in the treatment of Crohns disease in children and adolescents. J Pediatr 137:192-196
59. Jain S, Bandi V, Officer T,WolleyM, Guntupalli K (2006) Role of vocal cord function and dysfunction in patients presenting with symptoms of acute asthma exacerbation. J Asthma 43:207-212
60. Jiang H, Harris MB, Rothman P (2000) IL-4/IL-13 signaling beyond JAK/STAT. J Allergy Clin Immunol 105:1063-1070
61. Jones PW (2002) Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 19:398-404
62. Juniper E (1999) Health-related quality of life in asthma. Curr Opin Pulm Med 5:105-110
63. Juniper E, Guyatt G, Epstein R, Ferrie P, Jaeschke R, Hiller T (1992) Evaluation of impairment of health-related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 47:76-83
64. Keane J, Gershon S,Wise RP,Mirabile-Levens E, Kasznica J, SchwietermanWD, Siegel JN, Braun MM (2001) Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 345:1098-1104
65. Keatings VM, Jatakanon A,Worsdell YM, Barnes PJ (1997) Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 155:542-548
66. Kim J, McKinley L, Natarajan S, Bolgos GL, Siddiqui J, Copeland S, Remick DG (2006) Anti-tumor necrosis factor-alpha antibody treatment reduces pulmonary inflammation and methacholine hyper-responsiveness in a murine asthma model induced by house dust. Clin Exp Allergy 36:122-132
67. Kips JC, OConnor BJ, Langley SJ, Woodcock A, Kerstjens HAM, Postma DS, Danzig M, Cuss F, Pauwels RA (2003) Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 167:1655-1659
68. Kitaura J, Song J, Tsai M, Asai K, Maeda-Yamamoto M, Mocsai A, Kawakami Y, Liu F-T, Lowell CA, Barisas BG, Galli SJ, Kawakami T (2003) Evidence that IgE molecules mediate a spectrum of effects on mast cell survival and activation via aggregation of the Fc RI. PNAS 100:12911-12916
69. Kroegel C, Julius P, Matthys H, Virchow Jc, Jr., Luttmann W (1996) Endobronchial secretion of interleukin-13 following local allergen challenge in atopic asthma: relationship to interleukin-4 and eosinophil counts. Eur Respir J 9:899-904
70. Kroesen S, Widmer AF, Tyndall A, Hasler P (2003) Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-α therapy. Rheumatology 42:617-621
71. Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A, Leupold W, Bergmann K-C, Rolinck-Werninghaus C, Grave M (2002) Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 109:274-280
72. Kulczycki A, Isersky C, Metzger H (1974) The interaction of IgE with rat basophilic leukemia cells. I. Evidence for specific binding of IgE. J Exp Med 139:600-616
73. Leckie MJ, Brinke At, Khan J, Diamant Z, OConnor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R (2000) Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356:2144-2148
74. Lemanske RF, Jr., Nayak A, McAlary M, Everhard F, Fowler-Taylor A, Gupta N (2002) Omalizumab improves asthma-related quality of life in children with allergic asthma. Pediatrics 110:e55
75. Leung DYM, Sampson HA, Yunginger JW, Burks AW, Jr., Schneider LC, Wortel CH, Davis FM, Hyun JD, Shanahan WR, Jr., the TNXPASG (2003) Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 348:986-993
76. Li Y-F, Gauderman WJ, Avol E, Dubeau L, Gilliland FD (2006) Associations of tumor necrosis factor G-308A with childhood asthma and wheezing. Am J Respir Crit Care Med 173:970-976
77. Liu J, Lester P, Builder S, Shire SJ (1995) Characterization of Complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 34:10474-10482
78. Lugogo NL, Kraft M (2006) Epidemiology of asthma. Clin Chest Med 27:1-15
79. MacGlashan D (1993) Releasability of human basophils: cellular sensitivity and maximal histamine release are independent variables. J Allergy Clin Immunol 91:605-615
80. MacGlashan DW, Jr., Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, Sterbinsky SA, Hamilton RG, Lichtenstein LM (1997) Down-regulation of Fc RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 158:1438-1445
81. Malveaux F, Conroy M, Adkinson NJ, LM L (1978) IgE receptors on human basophils. Relationship to serum IgE concentration. J Clin Invest 62:176-181
82. Mannino DM, Homa DM, Akinbami LJ, Moorman JE, Gwynn C, Redd SC (2000) Surveillance for Asthma - United States, 1980-1999.
83. Marcus P (2006) Incorporating anti-IgE (omalizumab) therapy into pulmonary medicine practice: practice management implications. Chest 129:466-474
84. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ (1995) Asthma and wheezing in the first six years of life. N Engl J Med 332:133-138
85. Maurer D, Ebner C, Reininger B, Fiebiger E, Kraft D, Kinet JP, Stingl G (1995) The high affinity IgE receptor (Fc RI) mediates IgE-dependent allergen presentation. J Immunol 154:6285-6290
86. Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P (2001) Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 108:e36
87. Milgrom H, Fick R, Su J, Reimann J, Bush R,WatrousM,MetzgerW(1999a) Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 341:1966-1973
88. Milgrom H, Fick RB, Su JQ, Reimann JD, Bush RK, Watrous ML, Metzger WJ, The rhu MESG (1999b) Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 341:1966-1973
89. Mingomataj EC, Xhixha F, Gjata E (2006) Helminths can protect themselves against rejection inhibiting hostile respiratory allergy symptoms. Allergy 61:400-406
90. Mukhopadhyay S, Hoidal J, Mukherjee T (2006) Role of TNFα in pulmonary pathophysiology. Respir Res 7:125
91. NAEEP (1997) National Asthma Education and Prevention Program Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. NIH NAEEP (2002) Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma - Update on Selected Topics (2002). NIH NHLBI (1991) Guidelines for the Diagnosis and Management of Asthma: I. Definition and diagnosis. J Allergy Clin Immunol 88:427-438
92. NHLBI/WHO (2002) Global Initiative for asthma: global strategy for asthma management and prevention. NIH
93. Oba Y, Salzman GA ( 2004) Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol 114 265-269.
94. Ober C, Hoffjan S (2006) Asthma genetics 2006: the long and winding road to gene discovery. Genes Immunol 7:95-100
95. Oettgen HC, Geha RS (2001) IgE regulation and roles in asthma pathogenesis. J Allergy Clin Immunol 107:429-440
96. Ohkawara Y, Lei XF, Stampfli MR, Marshall JS, Xing Z, Jordana M (1997) Cytokine and eosinophil responses in the lung, peripheral blood, and bone marrow compartments in a murine model of allergen-induced airways inflammation. Am J Respir Cell Mol Biol 16:510-520
97. Ong YE, Menzies-Gow A, Barkans J, Benyahia F, Ou T-T, Ying S, Kay AB (2005) Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge. J Allergy Clin Immunol 116:558-564
98. Parks KW, Casale TB (2006) Anti-immunoglobulin E monoclonal antibody administered with immunotherapy. Allergy Asthma Proc 27:33-36
99. Pennings HJ, Kramer K, Bast A, Buurman WA, Wouters EF (1998) Tumour necrosis factor-alpha induces hyperreactivity in tracheal smooth muscle of the guinea-pig in vitro. Eur Respir J 12:45-49
100. Presta L, Shields R, OConnell L, Lahr S, Porter J, Gorman C, Jardieu P (1994) The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 269:26368-26373
101. Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, Jardieu PM (1993) Humanization of an antibody directed against IgE. J Immunol 151:2623-2632
102. Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB (2003) Omalizumab treatment downregulates dendritic cell Fc RI expression. J Allergy Clin Immunol 112:1147-1154
103. Prussin C,Metcalfe DD (2006) IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 117:S450-S456
104. Qureshi F, Pestian J, Davis P, Zaritsky A (1998) Effect of nebulized ipratropium on the hospitalization rates of children with asthma. N Engl J Med 339:1030-1035
105. Reeves MJ, Bohm SR, Korzeniewski SJ, Brown MD (2006) Asthma care and management before an emergency department visit in children in Western Michigan: how well does care adhere to guidelines? Pediatrics 117:S118-126
106. Rieves D (2003) FDA medical officers review of safety information on omalizumab in briefing BLA STN 103976/0. Food and Drug Administration, Washington, DC
107. Roberts NJ, Robinson DS, Partridge MR (2006) How is difficult asthma managed? Eur Respir J 28:968-973
108. Roskos LK, Davis CG, Schwab GM (2004) The clinical pharmacology of therapeutic monoclonal antibodies. Drug Development Res 61:108-120
109. Rychly D, DiPiro J (2005) Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 25:1181-1192
110. Saini SS, MacGlashan DW, Jr., Sterbinsky SA, Togias A, Adelman DC, Lichtenstein LM, Bochner BS (1999) Down-regulation of human basophil IgE and FC RIα surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol 162:5624-5630
111. Schulman ES (2001) Development of a monoclonal anti-immunoglobulin E antibody (Omalizumab) for the treatment of allergic respiratory disorders. Am J Respir Crit Care Med 164:6S-11
112. Scott DL, Kingsley GH (2006) Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 355:704-712
113. Shields R, Whether W, Zioncheck K, OConnell L, Fendly B, Presta L, Thomas D, Saban R, Jardieu P (1995) Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol 107:308-312
114. Slavin RG, Haselkorn T, Lee JH, Zheng B, Deniz Y, Wenzel SE (2006) Asthma in older adults: observations from the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study. Ann Allergy, Asthma Immunol 96:406-414
115. Soler M, Matz J, Townley R, Buhl R, OBrien J, Fox H, Thirlwell J, Gupta N, Della Cioppa G (2001) The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 18:254-261
116. Sporik R, Holgate ST, Platts-Mills TA, Cogswell JJ (1990) Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. A prospective study. N Engl J Med 323:502-507
117. Strunk RC, Bloomberg GR (2006) Omalizumab for Asthma. N Engl J Med 354:2689-2695
118. Strunk RC, Szefler SJ, Phillips BR, Zeiger RS, Chinchilli VM, Larsen G, Hodgdon K, Morgan W, Sorkness CA, Lemanske JRF (2003) Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children. J Allergy Clin Immunol 112:883-892
119. Thomas P, Heywood G (2002) Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma. Thorax 57:774-778
120. Thomas PS, Yates DH, Barnes PJ (1995) Tumor necrosis factor-alpha increases airway responsiveness and sputum neutrophilia in normal human subjects. Am J Respir Crit Care Med 152:76-80
121. Upham JW (2003) The role of dendritic cells in immune regulation and allergic airway inflammation. Respirology 8:140-148
122. van der Vaart H, Koeter GH, Postma DS, Kauffman HF, ten Hacken NHT (2005) First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 172:465-469
123. Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, Fox H, Surrey K (2004) Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 59:709-717
124. Walker S, Monteil M, Phelan K, Lasserson T, EHW (2006) Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev
125. Walsh GM (2005) Novel therapies for asthma - advances and problems. Curr Pharm Design 11:3027-3038
126. Walsh GM (2006) Targeting airway inflammation: novel therapies for the treatment of asthma. Curr Med Chem 13:3105-3111
127. Wijnhoven HAH, Kriegsman DMW, Hesselink AE, Penninx BWJH, de Haan M (2001) Determinants of different dimensions of disease severity in asthma and COPD: pulmonary function and health-related quality of life. Chest 119:1034-1042
128. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD (1998) Interleukin-13: central mediator of allergic asthma. Science 282:2258-2261
129. Wood KL, Hage CA, Knox KS, KleimanMB, Sannuti A, Day RB,Wheat LJ, Twigg HL, III (2003) Histoplasmosis after Treatment with Anti-Tumor Necrosis Factor-α Therapy. Am J Respir Crit Care Med 167:1279-1282
130. Yazdanbakhsh M, van den Biggelaar A, Maizels RM (2001) Th2 responses without atopy: immunoregulation in chronic helminth infections and reduced allergic disease. Trends Immunol 22:372-377
131. YiglaM, Tov N, Solomonov A, Rubin A, Harlev D (2003) Difficult-to-control asthma and obstructive sleep apnea. J Asthma 40:865-871